IDEXX LABORATORIES files 8-K/A amendment

TL;DR

IDEXX filed an amendment to an 8-K, likely correcting or adding info to prior financial disclosures.

AI Summary

IDEXX LABORATORIES, INC. filed an amendment (8-K/A) on October 31, 2024, to a previous report. This amendment pertains to the company's results of operations and financial condition, as well as financial statements and exhibits. The filing does not appear to contain new financial figures or operational updates but rather serves as an amendment to a prior disclosure.

Why It Matters

This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information regarding IDEXX's financial condition or operations.

Risk Assessment

Risk Level: low — This is an amendment to a previous filing, not a new material event, suggesting it's procedural or corrective.

Key Players & Entities

• IDEXX LABORATORIES, INC. (company) — Registrant
• October 31, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 000-19271 (filing_number) — Commission File Number
• 01-0393723 (tax_id) — IRS Employer Identification No.
• Westbrook, Maine (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.10 — ange on whichregistered Common Stock, $0.10 par value per share IDXX NASDAQ Glo

Filing Documents

• tm2427217d1_8ka.htm (8-K/A) — 37KB
• tm2427217d1_ex99-1.htm (EX-99.1) — 548KB
• tm2427217d1_8kaimg01.jpg (GRAPHIC) — 8KB
• tm2427217d1_ex99-1img001.jpg (GRAPHIC) — 3KB
• 0001104659-24-112975.txt ( ) — 819KB
• idxx-20241031.xsd (EX-101.SCH) — 3KB
• idxx-20241031_lab.xml (EX-101.LAB) — 33KB
• idxx-20241031_pre.xml (EX-101.PRE) — 22KB
• tm2427217d1_8ka_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On October 31, 2024, the Company filed the Original 8-K, which included the Original Earnings Release. This Amended 8-K replaces the Original Earnings Release with the amended earnings release, which is attached as Exhibit 99.1 to the Amended 8-K (the "Amended Earnings Release"). This Amended Earnings Release corrects and replaces the range of projected 2024 comparable operating profit margin expansion of 70 to 100 basis points set forth in the "2024 Growth and Financial Performance Outlook" section of the Company's Original Earnings Release with 30 to 60 basis points. All other information contained in the Original Earnings Release remains unchanged. See "Note Regarding Forward-Looking Statements" and "Statement Regarding Non-GAAP Financial Measures" for additional information. In accordance with general instructions to Form 8-K, the information in this Amended 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled "IDEXX Laboratories Announces Third Quarter Results," issued by the Company on October 31, 2024 (corrected). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES, INC. Date: October 31, 2024 By: /s/ Brian P. McKeon Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer 2

View Full Filing

View this 8-K/A filing on SEC EDGAR